Chondrosarcomas in adolescents: are they different?

Area of Science:

• Orthopedic Oncology
• Pediatric Oncology
• Skeletal Tumors

Background:

• Chondrosarcoma is a rare bone cancer, with pediatric and adolescent cases accounting for less than 5% of all diagnoses.
• Understanding the specific characteristics and outcomes of chondrosarcoma in young patients is crucial for tailored treatment strategies.

Purpose of the Study:

• To evaluate the clinical characteristics and oncologic outcomes of chondrosarcoma in patients aged 21 years or younger.
• To compare outcomes based on tumor type (primary vs. secondary) and location (pelvis vs. extremities).

Main Methods:

• Retrospective review of 11 patients (21 years or younger) treated for chondrosarcoma of the pelvis and extremities between 2006 and 2016.
• Analysis of surgical margins, adjuvant therapies, recurrence rates, and survival data.
• Statistical comparison of outcomes for primary versus secondary chondrosarcomas and pelvic versus extremity tumors.

Main Results:

• Secondary chondrosarcomas comprised over half (55%) of the cases in this young cohort.
• The 5-year overall and disease-free survival rates were 89%.
• No statistically significant differences in survival were observed between primary and secondary chondrosarcomas (P=0.061) or between pelvic and extremity tumors (P=0.264).

Conclusions:

• Chondrosarcoma in children and adolescents is rare, with secondary tumors being prevalent.
• Young patients with chondrosarcoma demonstrate oncologic outcomes comparable to adult populations.
• Surgical excision with clear margins is the primary treatment, with adjuvant therapies not administered in this series.